Experimental data both in vitro and in immunocompetent pre-clinical models have identified glutathione peroxidase 2 (GPX2), an Nrf2 target and a critical regulator of oxidative stress response, as a primary driver of suppressed immunity, manifested through reduced cytokine and chemokine production by tumor cells, development of tumors depleted of cytotoxic T cells, and enriched for myeloid derived suppressor cells. This evidence concerns the gene NFE2L2 and neoplasm.